Evidence map›Paper›PMID 28948418›Full record

ArticleBreast cancer research and treatment2018

Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.

Ying L Liu, Anurag Saraf, Benjamin Catanese, Shing M Lee, Yuan Zhang, Eileen P Connolly, Kevin Kalinsky

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 5 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Observational
  7. Review
  8. Review
  9. Article
  10. Obesity as a Risk Factor for Breast Cancer-The Role of miRNA.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ying L LiuDepartment of Medicine, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.
Anurag SarafDepartment of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.
Benjamin CataneseDepartment of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.
Shing M LeeDepartment of Biostatistics, Columbia University School of Medicine, New York, NY, USA.
Yuan ZhangDepartment of Biostatistics, Columbia University School of Medicine, New York, NY, USA.
Eileen P ConnollyDepartment of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.
Kevin KalinskyDepartment of Medical Oncology, New York Presbyterian Hospital, Columbia University Medical Center, 161 Fort Washington Ave, Rm 10-1071, New York, NY, 10032, USA. Kk2693@cumc.columbia.edu.
Columbia University · USColumbia University Irving Medical Center · USNew York Hospital Queens · USNewYork–Presbyterian Hospital · US

Funding

Clinical and Translational Science AwardKL2TR000081 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$3.3M
NCATS NIH HHS KL2 TR000081
6 · The paper itself

Abstract

backgroundObesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups.

methodsIn a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI ≥30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR+)/HER2-, HER2+, and Triple-Negative Breast Cancer (TNBC])] in our diverse population.

resultsMedian follow-up was 32.6 months (range 5.7-137.8 months). Overall, obesity was associated with worse EFS (HR 1.71, 95% CI 1.03-2.84, p = 0.04) and a trend towards worse OS (p = 0.13). In HR+/HER2- disease (n = 135), there was an interaction between obesity and hormonal therapy with respect to OS but not EFS. In those receiving tamoxifen (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96-89.3, p = 0.05). In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS. In TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03-6.66, p = 0.04) and a trend towards worse OS (p = 0.06). In HER2+ disease (n = 94), obesity was associated with a trend towards worse EFS (HR 3.37, 95% CI 0.97-11.72, p = 0.06) but not OS. Race/ethnicity was not associated with survival in any subtype, and there were no interactions with obesity on survival.

conclusionsObesity may negatively impact survival, with differences among tumor subtypes.

Indexed as

PrognosisAdultAgedBody Mass IndexBreast NeoplasmsBridged-Ring CompoundsChemotherapy, AdjuvantDisease-Free SurvivalDoxorubicinEthnicityFemaleHumansKaplan-Meier EstimateMiddle AgedNeoadjuvant TherapyObesityBridged-Ring CompoundsDoxorubicintaxaneTaxoidsBreast cancerNeoadjuvant chemotherapyObesityRace/ethnicitySurvivalTumor subtype

Identifiers

PMID28948418
PMCPMC5790631
OpenAlexW2759499908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.